| Literature DB >> 26259532 |
Bálint Tobiás1, Csaba Halászlaki2, Bernadett Balla2, János P Kósa2,3, Kristóf Árvai3, Péter Horváth2, István Takács2, Zsolt Nagy2, Evelin Horváth2, János Horányi4, Balázs Járay5, Eszter Székely5, Tamás Székely5, Gabriella Győri6, Zsuzsanna Putz2, Magdolna Dank2, Zsuzsanna Valkusz7, Béla Vasas8, Béla Iványi8, Péter Lakatos2.
Abstract
The incidence of thyroid cancers is increasing worldwide. Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer. In our study, we analyzed these genetic alterations in 394 thyroid tissue samples (197 papillary carcinomas and 197 healthy). The somatic mutations and translocations were detected by Light Cycler melting method and Real-Time Polymerase Chain Reaction techniques, respectively. In tumorous samples, 86 BRAF (44.2%), 5 NRAS (3.1%), 2 HRAS (1.0%) and 1 KRAS (0.5%) mutations were found, as well as 9 RET/PTC1 (4.6%) and 1 RET/PTC3 (0.5%) translocations. No genetic alteration was seen in the non tumorous control thyroid tissues. No correlation was detected between the genetic variants and the pathological subtypes of papillary cancer as well as the severity of the disease. Our results are only partly concordant with the data found in the literature.Entities:
Keywords: BRAF; Mutation; Papillary thyroid cancer; RAS; RET/PTC
Mesh：
Substances：
Year: 2015 PMID： 26259532 DOI： 10.1007/s12253-015-9969-9
Source DB: PubMed Journal: Pathol Oncol Res ISSN： 1219-4956 Impact factor: 3.201